<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37262073</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1553-7374</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>PLoS pathogens</Title><ISOAbbreviation>PLoS Pathog</ISOAbbreviation></Journal><ArticleTitle>Antibody signatures in hospitalized hand, foot and mouth disease patients with acute enterovirus A71 infection.</ArticleTitle><Pagination><StartPage>e1011420</StartPage><MedlinePgn>e1011420</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1011420</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.ppat.1011420</ELocationID><Abstract><AbstractText>Enterovirus A71 (EV-A71) infection is a major cause of severe hand, foot and mouth disease (HFMD) in young children. The characteristics of EV-A71 neutralizing antibodies in HFMD patients are not well understood. In this study, we identified and cloned EV-A71-neutralizing antibodies by single cell RNA and B cell receptor sequencing of peripheral blood mononuclear cells. From 145 plasmablasts, we identified two IgG1 monoclonal antibodies (mAbs) and six IgM mAbs that neutralized EV-A71. Four of the IgM mAbs harbor germline variable sequences and neutralize EV-A71 potently. Two genetically similar IgM antibodies from two patients have recurrent heavy chain variable domain gene usage and similar complementarity-determining region 3 sequences. We mapped the residues of EV-A71 critical for neutralization through selection of virus variants resistant to antibody neutralization in the presence of neutralizing mAbs. The residues critical for neutralization are conserved among EV-A71 genotypes. Epitopes for the two genetically similar antibodies overlap with the SCARB2 binding site of EV-A71. We used escape variants to measure the epitope-specific antibody response in acute phase serum samples from EV-A71 infected HFMD patients. We found that these epitopes are immunogenic and contributed to the neutralizing antibody response against the virus. Our findings advance understanding of antibody response to EV-A71 infection in young children and have translational potential: the IgM mAbs could potentially be used for prevention or treatment of EV-A71 infections.</AbstractText><CopyrightInformation>Copyright: © 2023 You et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>You</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Savaid Medical School, University of Chinese Academy of Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Junbo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Yibing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Chinese Centre for Disease Control and Prevention, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yao-Qing</ForeName><Initials>YQ</Initials><AffiliationInfo><Affiliation>School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ying</LastName><ForeName>Tianlei</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Basic Medical Sciences, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turtle</LastName><ForeName>Lance</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Hongjie</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-6335-5648</Identifier><AffiliationInfo><Affiliation>Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Pathog</MedlineTA><NlmUniqueID>101238921</NlmUniqueID><ISSNLinking>1553-7366</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007075">Immunoglobulin M</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="Y">Hand, Foot and Mouth Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007075" MajorTopicYN="N">Immunoglobulin M</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>I have read the journal’s policy and the authors of this manuscript have the following competing interests: H.Yu has received research funding from Sanofi Pasteur, GlaxoSmithKline, Yichang HEC Changjiang Pharmaceutical Company, Shanghai Roche Pharmaceutical Company, and SINOVAC Biotech Ltd. None of those research funding is related to this work. All other authors report no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>1</Day><Hour>23</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>1</Day><Hour>13</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37262073</ArticleId><ArticleId IdType="pmc">PMC10263328</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.1011420</ArticleId><ArticleId IdType="pii">PPATHOGENS-D-22-01951</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yang B, Liu F, Liao Q, Wu P, Chang Z, Huang J, et al.. Epidemiology of hand, foot and mouth disease in China, 2008 to 2015 prior to the introduction of EV-A71 vaccine. Euro Surveill. 2017;22(50). doi: 10.2807/1560-7917.ES.2017.22.50.16-00824 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2017.22.50.16-00824</ArticleId><ArticleId IdType="pmc">PMC5743100</ArticleId><ArticleId IdType="pubmed">29258646</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. A guide to clinical management and public health response for hand, foot and mouth disease (HFMD).
2011; Available from: https://iris.wpro.who.int/handle/10665.1/5521.</Citation></Reference><Reference><Citation>Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 2010;9(11):1097–1105. doi: 10.1016/S1474-4422(10)70209-X .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70209-X</ArticleId><ArticleId IdType="pubmed">20965438</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardoso MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infectious Diseases. 2010;10(11):778–790. WOS:000283912800024. doi: 10.1016/S1473-3099(10)70194-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Tan X, Cui A, Mao N, Xu S, Zhu Z, et al.. Complete genome analysis of the C4 subgenotype strains of enterovirus 71: predominant recombination C4 viruses persistently circulating in China for 14 years. PLoS One. 2013;8(2):e56341. doi: 10.1371/journal.pone.0056341 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0056341</ArticleId><ArticleId IdType="pmc">PMC3575343</ArticleId><ArticleId IdType="pubmed">23441179</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi K, Koike S. Cellular receptors for enterovirus A71. J Biomed Sci. 2020;27(1):23. doi: 10.1186/s12929-020-0615-9 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-020-0615-9</ArticleId><ArticleId IdType="pmc">PMC6954530</ArticleId><ArticleId IdType="pubmed">31924205</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H, Sun L, Lin J, He J, Deng A, Kang M, et al.. Protective effect of exclusive breastfeeding against hand, foot and mouth disease. BMC Infect Dis. 2014;14:645. doi: 10.1186/s12879-014-0645-6 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-014-0645-6</ArticleId><ArticleId IdType="pmc">PMC4273484</ArticleId><ArticleId IdType="pubmed">25471294</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, et al.. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381(9882):2024–2032. doi: 10.1016/S0140-6736(13)61049-1 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61049-1</ArticleId><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Liu L, Mo Z, Wang X, Xia J, Liang Z, et al.. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med. 2014;370(9):829–837. doi: 10.1056/NEJMoa1303224 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1303224</ArticleId><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, et al.. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370(9):818–828. doi: 10.1056/NEJMoa1304923 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304923</ArticleId><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P, Liu CC, Chow YH, Chou AH, Klein M. Review of enterovirus 71 vaccines. Clin Infect Dis. 2015;60(5):797–803. doi: 10.1093/cid/ciu852 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciu852</ArticleId><ArticleId IdType="pubmed">25352588</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Xu L, He D, Yang L, Liu C, Chen Y, et al.. In vivo time-related evaluation of a therapeutic neutralization monoclonal antibody against lethal enterovirus 71 infection in a mouse model. PLoS One. 2014;9(10):e109391. doi: 10.1371/journal.pone.0109391 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0109391</ArticleId><ArticleId IdType="pmc">PMC4184856</ArticleId><ArticleId IdType="pubmed">25279734</ArticleId></ArticleIdList></Reference><Reference><Citation>Han JF, Cao RY, Deng YQ, Tian X, Jiang T, Qin ED, et al.. Antibody dependent enhancement infection of enterovirus 71 in vitro and in vivo. Virol J. 2011;8:106. doi: 10.1186/1743-422X-8-106. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-8-106</ArticleId><ArticleId IdType="pmc">PMC3060144</ArticleId><ArticleId IdType="pubmed">21385398</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C, Deng C, Wan J, Zhu L, Leng Q. Neutralizing antibody response in the patients with hand, foot and mouth disease to enterovirus 71 and its clinical implications. Virol J. 2011;8:306. doi: 10.1186/1743-422X-8-306 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-8-306</ArticleId><ArticleId IdType="pmc">PMC3142239</ArticleId><ArticleId IdType="pubmed">21679417</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang KY, Lin JJ, Chiu CH, Yang S, Tsao KC, Huang YC, et al.. A Potent Virus-Specific Antibody-Secreting Cell Response to Acute Enterovirus 71 Infection in Children. J Infect Dis. 2015;212(5):808–817. doi: 10.1093/infdis/jiv094 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiv094</ArticleId><ArticleId IdType="pubmed">25712974</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z, Ren X, Yang J, Dong J, Xue Y, Sun L, et al.. An elaborate landscape of the human antibody repertoire against enterovirus 71 infection is revealed by phage display screening and deep sequencing. MAbs. 2017;9(2):342–349. doi: 10.1080/19420862.2016.1267086 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19420862.2016.1267086</ArticleId><ArticleId IdType="pmc">PMC5297520</ArticleId><ArticleId IdType="pubmed">27929745</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthur Huang KY, Chen MF, Huang YC, Shih SR, Chiu CH, Lin JJ, et al.. Epitope-associated and specificity-focused features of EV71-neutralizing antibody repertoires from plasmablasts of infected children. Nat Commun. 2017;8(1):762. doi: 10.1038/s41467-017-00736-9 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00736-9</ArticleId><ArticleId IdType="pmc">PMC5624920</ArticleId><ArticleId IdType="pubmed">28970483</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Su B, Guo X, Sun W, Deng Y, Bao L, et al.. Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells. Cell. 2020;182(1):73–84 e16. doi: 10.1016/j.cell.2020.05.025 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.05.025</ArticleId><ArticleId IdType="pmc">PMC7231725</ArticleId><ArticleId IdType="pubmed">32425270</ArticleId></ArticleIdList></Reference><Reference><Citation>Song C, Li Y, Zhou Y, Liang L, Turtle L, Wang F, et al.. Enterovirus genomic load and disease severity among children hospitalised with hand, foot and mouth disease. EBioMedicine. 2020;62:103078. doi: 10.1016/j.ebiom.2020.103078 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2020.103078</ArticleId><ArticleId IdType="pmc">PMC7653080</ArticleId><ArticleId IdType="pubmed">33161231</ArticleId></ArticleIdList></Reference><Reference><Citation>Nutt SL, Hodgkin PD, Tarlinton DM, Corcoran LM. The generation of antibody-secreting plasma cells. Nat Rev Immunol. 2015;15(3):160–171. doi: 10.1038/nri3795 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3795</ArticleId><ArticleId IdType="pubmed">25698678</ArticleId></ArticleIdList></Reference><Reference><Citation>Wrammert J, Onlamoon N, Akondy RS, Perng GC, Polsrila K, Chandele A, et al.. Rapid and massive virus-specific plasmablast responses during acute dengue virus infection in humans. J Virol. 2012;86(6):2911–2918. doi: 10.1128/JVI.06075-11 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.06075-11</ArticleId><ArticleId IdType="pmc">PMC3302324</ArticleId><ArticleId IdType="pubmed">22238318</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren X, Wen W, Fan X, Hou W, Su B, Cai P, et al.. COVID-19 immune features revealed by a large-scale single cell transcriptome atlas. Cell. 2021. 10.1016/j.cell.2021.01.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.01.053</ArticleId><ArticleId IdType="pmc">PMC8582084</ArticleId><ArticleId IdType="pubmed">34767776</ArticleId></ArticleIdList></Reference><Reference><Citation>Giudicelli V, Brochet X, Lefranc MP. IMGT/V-QUEST: IMGT standardized analysis of the immunoglobulin (IG) and T cell receptor (TR) nucleotide sequences. Cold Spring Harb Protoc. 2011;2011(6):695–715. doi: 10.1101/pdb.prot5633 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/pdb.prot5633</ArticleId><ArticleId IdType="pubmed">21632778</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520. doi: 10.3389/fimmu.2014.00520 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2014.00520</ArticleId><ArticleId IdType="pmc">PMC4202688</ArticleId><ArticleId IdType="pubmed">25368619</ArticleId></ArticleIdList></Reference><Reference><Citation>Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A, et al.. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020. 10.1038/s41586-020-2456-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2456-9</ArticleId><ArticleId IdType="pmc">PMC7442695</ArticleId><ArticleId IdType="pubmed">32555388</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson KJ, Liu Y, Roskin KM, Glanville J, Hoh RA, Seo K, et al.. Human responses to influenza vaccination show seroconversion signatures and convergent antibody rearrangements. Cell Host Microbe. 2014;16(1):105–114. doi: 10.1016/j.chom.2014.05.013 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2014.05.013</ArticleId><ArticleId IdType="pmc">PMC4158033</ArticleId><ArticleId IdType="pubmed">24981332</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Zhang Z, Schramm CA, Joyce MG, Kwon YD, Zhou T, et al.. Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection. Cell. 2015;161(3):470–485. doi: 10.1016/j.cell.2015.03.004 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.03.004</ArticleId><ArticleId IdType="pmc">PMC4706178</ArticleId><ArticleId IdType="pubmed">25865483</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu L, Xu K, Wang N, Cao L, Wu J, Gao Q, et al.. Neutralization Mechanisms of Two Highly Potent Antibodies against Human Enterovirus 71. MBio. 2018;9(4). doi: 10.1128/mBio.01013-18. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.01013-18</ArticleId><ArticleId IdType="pmc">PMC6030555</ArticleId><ArticleId IdType="pubmed">29970466</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku Z, Ye X, Shi J, Wang X, Liu Q, Huang Z. Single Neutralizing Monoclonal Antibodies Targeting the VP1 GH Loop of Enterovirus 71 Inhibit both Virus Attachment and Internalization during Viral Entry. J Virol. 2015;89(23):12084–12095. doi: 10.1128/JVI.02189-15 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02189-15</ArticleId><ArticleId IdType="pmc">PMC4645313</ArticleId><ArticleId IdType="pubmed">26401034</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson BS, Moesker B, Smit JM, Wilschut J, Diamond MS, Fremont DH. A therapeutic antibody against west nile virus neutralizes infection by blocking fusion within endosomes. PLoS Pathog. 2009;5(5):e1000453. doi: 10.1371/journal.ppat.1000453 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1000453</ArticleId><ArticleId IdType="pmc">PMC2679195</ArticleId><ArticleId IdType="pubmed">19478866</ArticleId></ArticleIdList></Reference><Reference><Citation>Suryadevara N, Shrihari S, Gilchuk P, VanBlargan LA, Binshtein E, Zost SJ, et al.. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. Cell. 2021;184(9):2316–2331 e2315. doi: 10.1016/j.cell.2021.03.029 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.03.029</ArticleId><ArticleId IdType="pmc">PMC7962591</ArticleId><ArticleId IdType="pubmed">33773105</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou D, Zhao Y, Kotecha A, Fry EE, Kelly JT, Wang X, et al.. Unexpected mode of engagement between enterovirus 71 and its receptor SCARB2. Nat Microbiol. 2019;4(3):414–419. doi: 10.1038/s41564-018-0319-z .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-018-0319-z</ArticleId><ArticleId IdType="pubmed">30531980</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Peng W, Ren J, Hu Z, Xu J, Lou Z, et al.. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol. 2012;19(4):424–429. doi: 10.1038/nsmb.2255 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2255</ArticleId><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>Cauchemez S, Horby P, Fox A, Mai le Q, Thanh le T, Thai PQ, et al.. Influenza infection rates, measurement errors and the interpretation of paired serology. PLoS Pathog. 2012;8(12):e1003061. doi: 10.1371/journal.ppat.1003061 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003061</ArticleId><ArticleId IdType="pmc">PMC3521724</ArticleId><ArticleId IdType="pubmed">23271967</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu F, Yan Q, Wang H, Niu J, Li L, Zhu F, et al.. Performance of detecting IgM antibodies against enterovirus 71 for early diagnosis. PLoS One. 2010;5(6):e11388. doi: 10.1371/journal.pone.0011388 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0011388</ArticleId><ArticleId IdType="pmc">PMC2894942</ArticleId><ArticleId IdType="pubmed">20613983</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohannon C, Powers R, Satyabhama L, Cui A, Tipton C, Michaeli M, et al.. Long-lived antigen-induced IgM plasma cells demonstrate somatic mutations and contribute to long-term protection. Nat Commun. 2016;7:11826. doi: 10.1038/ncomms11826 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms11826</ArticleId><ArticleId IdType="pmc">PMC4899631</ArticleId><ArticleId IdType="pubmed">27270306</ArticleId></ArticleIdList></Reference><Reference><Citation>Skountzou I, Satyabhama L, Stavropoulou A, Ashraf Z, Esser ES, Vassilieva E, et al.. Influenza virus-specific neutralizing IgM antibodies persist for a lifetime. Clin Vaccine Immunol. 2014;21(11):1481–1489. doi: 10.1128/CVI.00374-14 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00374-14</ArticleId><ArticleId IdType="pmc">PMC4248769</ArticleId><ArticleId IdType="pubmed">25165027</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvert AE, Horiuchi K, Boroughs KL, Ong YT, Anderson KM, Biggerstaff BJ, et al.. The Specificity of the Persistent IgM Neutralizing Antibody Response in Zika Virus Infections among Individuals with Prior Dengue Virus Exposure. J Clin Microbiol. 2021;59(8):e0040021. doi: 10.1128/JCM.00400-21 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00400-21</ArticleId><ArticleId IdType="pmc">PMC8288270</ArticleId><ArticleId IdType="pubmed">33980647</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamond MS, Sitati EM, Friend LD, Higgs S, Shrestha B, Engle M. A critical role for induced IgM in the protection against West Nile virus infection. J Exp Med. 2003;198(12):1853–1862. doi: 10.1084/jem.20031223 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20031223</ArticleId><ArticleId IdType="pmc">PMC2194144</ArticleId><ArticleId IdType="pubmed">14662909</ArticleId></ArticleIdList></Reference><Reference><Citation>Chua CL, Sam IC, Chiam CW, Chan YF. The neutralizing role of IgM during early Chikungunya virus infection. PLoS One. 2017;12(2):e0171989. doi: 10.1371/journal.pone.0171989 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0171989</ArticleId><ArticleId IdType="pmc">PMC5300252</ArticleId><ArticleId IdType="pubmed">28182795</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorfmeier CL, Shen S, Tzvetkov EP, McGettigan JP. Reinvestigating the role of IgM in rabies virus postexposure vaccination. J Virol. 2013;87(16):9217–9222. doi: 10.1128/JVI.00995-13 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00995-13</ArticleId><ArticleId IdType="pmc">PMC3754079</ArticleId><ArticleId IdType="pubmed">23760250</ArticleId></ArticleIdList></Reference><Reference><Citation>Harada Y, Muramatsu M, Shibata T, Honjo T, Kuroda K. Unmutated immunoglobulin M can protect mice from death by influenza virus infection. J Exp Med. 2003;197(12):1779–1785. doi: 10.1084/jem.20021457 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20021457</ArticleId><ArticleId IdType="pmc">PMC2193959</ArticleId><ArticleId IdType="pubmed">12796467</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato M, Tsuji-Kawahara S, Kawasaki Y, Kinoshita S, Chikaishi T, Takamura S, et al.. Class switch recombination and somatic hypermutation of virus-neutralizing antibodies are not essential for control of friend retrovirus infection. J Virol. 2015;89(2):1468–1473. doi: 10.1128/JVI.02293-14 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02293-14</ArticleId><ArticleId IdType="pmc">PMC4300674</ArticleId><ArticleId IdType="pubmed">25378499</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilaratanakul V, Chen J, Tran O, Baxter VK, Troisi EM, Yeh JX, et al.. Germ Line IgM Is Sufficient, but Not Required, for Antibody-Mediated Alphavirus Clearance from the Central Nervous System. J Virol. 2018;92(7). doi: 10.1128/JVI.02081-17 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02081-17</ArticleId><ArticleId IdType="pmc">PMC5972861</ArticleId><ArticleId IdType="pubmed">29321331</ArticleId></ArticleIdList></Reference><Reference><Citation>Gil-Cruz C, Perez-Shibayama C, Firner S, Waisman A, Bechmann I, Thiel V, et al.. T helper cell- and CD40-dependent germline IgM prevents chronic virus-induced demyelinating disease. Proc Natl Acad Sci U S A. 2012;109(4):1233–1238. doi: 10.1073/pnas.1115154109 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1115154109</ArticleId><ArticleId IdType="pmc">PMC3268283</ArticleId><ArticleId IdType="pubmed">22232667</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke DS, Lorsomrudee W, Leake CJ, Hoke CH, Nisalak A, Chongswasdi V, et al.. Fatal outcome in Japanese encephalitis. Am J Trop Med Hyg. 1985;34(6):1203–1210. doi: 10.4269/ajtmh.1985.34.1203 .</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.1985.34.1203</ArticleId><ArticleId IdType="pubmed">3010752</ArticleId></ArticleIdList></Reference><Reference><Citation>Michaud E, Mastrandrea C, Rochereau N, Paul S. Human Secretory IgM: An Elusive Player in Mucosal Immunity. Trends Immunol. 2020;41(2):141–156. doi: 10.1016/j.it.2019.12.005 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2019.12.005</ArticleId><ArticleId IdType="pubmed">31928913</ArticleId></ArticleIdList></Reference><Reference><Citation>Persson H, Kirik U, Thörnqvist L, Greiff L, Levander F, Ohlin M. In Vitro Evolution of Antibodies Inspired by In Vivo Evolution. Front Immunol. 2018;9:1391. doi: 10.3389/fimmu.2018.01391 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01391</ArticleId><ArticleId IdType="pmc">PMC6021498</ArticleId><ArticleId IdType="pubmed">29977238</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X, Yu F, Wu Y, Ying T. Potent germline-like monoclonal antibodies: rapid identification of promising candidates for antibody-based antiviral therapy. Antib Ther. 2021;4(2):89–98. doi: 10.1093/abt/tbab008 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/abt/tbab008</ArticleId><ArticleId IdType="pmc">PMC8178282</ArticleId><ArticleId IdType="pubmed">34104872</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku Z, Xie X, Hinton PR, Liu X, Ye X, Muruato AE, et al.. Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants. Nature. 2021;595(7869):718–723. doi: 10.1038/s41586-021-03673-2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03673-2</ArticleId><ArticleId IdType="pmc">PMC8742224</ArticleId><ArticleId IdType="pubmed">34082438</ArticleId></ArticleIdList></Reference><Reference><Citation>Keyt BA, Baliga R, Sinclair AM, Carroll SF, Peterson MS. Structure, Function, and Therapeutic Use of IgM Antibodies. Antibodies (Basel). 2020;9(4). doi: 10.3390/antib9040053 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antib9040053</ArticleId><ArticleId IdType="pmc">PMC7709107</ArticleId><ArticleId IdType="pubmed">33066119</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong S, Tomusange K, Kulkarni V, Adeniji OS, Lakhashe SK, Hariraju D, et al.. Anti-HIV IgM protects against mucosal SHIV transmission. Aids. 2018;32(11):F5–f13. doi: 10.1097/QAD.0000000000001857 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0000000000001857</ArticleId><ArticleId IdType="pmc">PMC6380498</ArticleId><ArticleId IdType="pubmed">29762161</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CW, Sam IC, Lee VS, Wong HV, Chan YF. VP1 residues around the five-fold axis of enterovirus A71 mediate heparan sulfate interaction. Virology. 2017;501:79–87. doi: 10.1016/j.virol.2016.11.009 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2016.11.009</ArticleId><ArticleId IdType="pubmed">27875780</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y, Lee H, Hafenstein S, Kataoka C, Wakita T, Bergelson JM, et al.. Enterovirus 71 binding to PSGL-1 on leukocytes: VP1-145 acts as a molecular switch to control receptor interaction. PLoS Pathog. 2013;9(7):e1003511. doi: 10.1371/journal.ppat.1003511 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003511</ArticleId><ArticleId IdType="pmc">PMC3723564</ArticleId><ArticleId IdType="pubmed">23935488</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang SC, Li WC, Chen GW, Tsao KC, Huang CG, Huang YC, et al.. Genetic characterization of enterovirus 71 isolated from patients with severe disease by comparative analysis of complete genomes. J Med Virol. 2012;84(6):931–939. doi: 10.1002/jmv.23287 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.23287</ArticleId><ArticleId IdType="pubmed">22499017</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Zou Q, Chen L, Zhang H, Wang Y. Molecular analysis of virulent determinants of enterovirus 71. PLoS One. 2011;6(10):e26237. doi: 10.1371/journal.pone.0026237 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0026237</ArticleId><ArticleId IdType="pmc">PMC3198388</ArticleId><ArticleId IdType="pubmed">22039449</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke X, Zhang Y, Liu Y, Miao Y, Zheng C, Luo D, et al.. A Single Mutation in the VP1 Gene of Enterovirus 71 Enhances Viral Binding to Heparan Sulfate and Impairs Viral Pathogenicity in Mice. Viruses. 2020;12(8). doi: 10.3390/v12080883 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12080883</ArticleId><ArticleId IdType="pmc">PMC7472116</ArticleId><ArticleId IdType="pubmed">32823486</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Zhou Y, Cheng Y, Wu P, Zhou C, Cui P, et al.. Effectiveness of EV-A71 vaccination in prevention of paediatric hand, foot, and mouth disease associated with EV-A71 virus infection requiring hospitalisation in Henan, China, 2017–18: a test-negative case-control study. Lancet Child Adolesc Health. 2019;3(10):697–704. doi: 10.1016/S2352-4642(19)30185-3 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(19)30185-3</ArticleId><ArticleId IdType="pmc">PMC8713082</ArticleId><ArticleId IdType="pubmed">31375313</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith K, Garman L, Wrammert J, Zheng NY, Capra JD, Ahmed R, et al.. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat Protoc. 2009;4(3):372–384. doi: 10.1038/nprot.2009.3 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2009.3</ArticleId><ArticleId IdType="pmc">PMC2750034</ArticleId><ArticleId IdType="pubmed">19247287</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>